Comparison of PD-L1 Immunostain Concordance of SP263 and SP142 Across Different Tumor Types

被引：0
|
作者：
Nakasaki, Manando [1 ]
Fadare, Oluwole [1 ]
Patel, Sandip [1 ]
Hansel, Donna [1 ]
机构：
[1] Univ Calif San Diego, La Jolla, CA 92093 USA
来源：
LABORATORY INVESTIGATION | 2017年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
2140
引用
收藏
页码：532A / 532A
页数：1
相关论文
共 50 条
  • [41] Study on the heterogeneity of expression of PD-L1 (Ventana SP142) in breast cancer in space and time
    He, J.
    Liu, Y.
    VIRCHOWS ARCHIV, 2021, 479 (SUPPL 1) : S70 - S70
  • [42] PD-L1 (SP142) Immunohistochemistry in Clinical Metastatic Breast Carcinomas and its Association with Survival
    Shafi, Saba
    Challa, Bindu
    Parwani, Anil
    Li, Zaibo
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 192 - 194
  • [43] External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different
    Dodson, Andrew
    Parry, Suzanne
    Lissenberg-Witte, Birgit
    Haragan, Alex
    Allen, David
    O'Grady, Anthony
    McClean, Emma
    Hughes, Jamie
    Miller, Keith
    Thunnissen, Erik
    JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2020, 6 (02): : 138 - 145
  • [44] PD-L1 (SP142) Immunohistochemistry in Clinical Metastatic Breast Carcinomas and its Association with Survival
    Shafi, Saba
    Challa, Bindu
    Parwani, Anil
    Li, Zaibo
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 192 - 194
  • [45] Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N
    Jacquelyn Smith
    Mark D. Robida
    Krista Acosta
    Bharathi Vennapusa
    Amita Mistry
    Greg Martin
    Alton Yates
    H. James Hnatyszyn
    Diagnostic Pathology, 11
  • [46] Assessment of heterogeneity of PD-L1 expression in NSCLC, HNSCC, and UC with Ventana SP263 assay.
    Scott, Marietta L.
    Scorer, Paul
    Lawson, Nicola
    Ratcliffe, Marianne J.
    Barker, Craig
    Rebelatto, Marlon
    Walker, Jill
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [47] Interobserver agreement of PD-L1 (SP263) assessment in advanced NSCLC on cytological smears and histological samples
    Ambrosi, Francesca
    Giunchi, Francesca
    Capizzi, Elisa
    Cancellieri, Alessandra
    Trisolini, Rocco
    Ardizzoni, Andrea
    Fiorentino, Michelangelo
    Ricci, Costantino
    PATHOLOGY RESEARCH AND PRACTICE, 2022, 233
  • [48] Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N
    Smith, Jacquelyn
    Robida, Mark D.
    Acosta, Krista
    Vennapusa, Bharathi
    Mistry, Amita
    Martin, Greg
    Yates, Alton
    Hnatyszyn, H. James
    DIAGNOSTIC PATHOLOGY, 2016, 11
  • [49] Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
    Sung Gwe Ahn
    Seon-Kyu Kim
    Jonathan H. Shepherd
    Yoon Jin Cha
    Soong June Bae
    Chungyeul Kim
    Joon Jeong
    Charles M. Perou
    Breast Cancer Research and Treatment, 2021, 188 : 165 - 178
  • [50] PD-L1 (SP142) testing is concordant between Benchmark Ultra and Bond-III stainers
    Eva Compérat
    André Oszwald
    Gabriel Wasinger
    Justine Wacquet
    Morgan Rouprêt
    Olivier Cussenot
    World Journal of Urology, 2021, 39 : 4067 - 4071
12345